Eris Lifesciences inks deal with Natco Pharma for weight-loss drug semaglutide
The collaboration will leverage Eris’s commercial presence in the diabetes segment and Natco’s manufacturing and regulatory prowess in complex formulations
Business
The collaboration will leverage Eris’s commercial presence in the diabetes segment and Natco’s manufacturing and regulatory prowess in complex formulations
Chief executive Jacob Aarup-Andersen said in a February earnings call that the company is assessing an initial public offering in…
Warren Buffett believes you do not need an economist to make decisions on buying stocks or companies, viewing short-term economic…
Eternal’s Deepinder Goyal’s startup LAT Aerospace has acquired Gurugram-based early-stage defence robotic startup named Sharang Shakti as the company plans…
Tata Group has reportedly deferred its decision on Chairman N Chandrasekaran’s reappointment to his role for another five years, as…
With this additional lease, Apple’s total area in Embassy Zenith is now 389,000 sq. ft, with a monthly rent of…
The next phase of growth will be driven by smaller cities and middle-income groups, according to the BCG report. The…
HCL Technologies CEO C. Vijayakumar addressed concerns over AI’s impact on IT services, asserting a gradual transition rather than a…
Vivriti Next, the unified entity, will expand beyond mid-market lending into tech-driven advisory and capital markets services ahead of a…
Airtel and its promoter group will invest ₹20,000 crore in Airtel Money, its new non-bank arm, competing with Jio Financial…